Market Trends of Cell Dissociation Industry
Pharmaceutical and Biotechnology Companies Segment is Expected to Witness a Healthy Growth Over the Forecast Period
The increasing focus of biopharmaceutical companies on new drug development and increasing R&D is augmenting the demand for cell dissociation across such companies.
In recent years, there has been a growing demand for biopharmaceuticals due to surging cases of cancer and other life-threatening diseases. There has been a rise in the demand for targeted therapies in recent years. For instance, an article by Pharmaceutical Technology, updated in August 2021, indicated that innovative, novel biologics help in the growth of the biopharmaceutical market, as improved processes and technological developments are aiding in changing the future of manufacturing. Manufacturers of biosimilars are offering less expensive alternatives to many of the monoclonal antibody medications that generate the most revenue in the market at reduced clinical and R&D expenditures.
Also, an article from PubMed published in March 2022 indicated an increase in the demand for biopharmaceuticals, which had prompted the emergence of a business model called 'contract development manufacturing organization (CDMO)' that aids in the development and manufacturing processes. The CDMOs could efficiently manufacture larger volumes of the required biopharmaceutical product, meeting the increasing demands.
Thus, owing to these factors, the segment is expected to grow significantly over the forecast period.
North America is Expected to Hold Significant Share of the Market
The cell dissociation market in the North American region is expected to witness significant growth owing to factors such as the highly advanced biopharmaceutical industry, which allows extensive R&D of novel therapeutics and increasing company investment to develop new therapies.
According to the Cancer Facts & Figures 2023 data published by the American Cancer Society, an estimated 1.9 million new cancer cases will be diagnosed and 0.6 million cancer deaths in the United States (US) in 2023. In addition, in the US, the population aged 65 or more was 54.1 million (16% of the total population) in 2019, estimated at 21.6% by 2040. Hence, the prevalence of chronic diseases coupled with the increasing geriatric population in the country is anticipated to create more opportunities for developing new biopharmaceuticals, driving the studied market growth.
Moreover, the incidence of Cancer, cardiovascular diseases (CVDs), and diabetes creates demand for new biopharmaceuticals. For instance, as per the Canadian Cancer Statistics 2021 released in November 2021, an estimated 229,200 Canadians were diagnosed with Cancer in 2021. Also, according to the estimates, the death rates for the three leading cancer types in 2021 were lung cancer (25%), colorectal Cancer (11%), and pancreatic Cancer (7%). With these estimates, it was reported that Cancer remained one of Canada's leading causes of death in 2021. Thus creating opportunities for new therapies in the country and driving the studied market growth.
